Skip to main content
Equibles
NNVC logo

NNVC · Nanoviricides, Inc.

Track NNVC — free

Use NNVC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NNVC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.44 +0.04 (+2.86%) At close · Oct 7
Rebalance outlook locked
Going-concern doubt — flagged Sep 28, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-K filed Sep 28, 2026
Market Cap
$36.76M
Shares
25.52M
Volume · Oct 7 306.21K Avg daily vol (3M) 447.94K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.44 Open$1.43 Day$1.40–1.50 52W close$0.85–2.03 Avg vol 30d564K Short int588K · 2.3% float · 1.3d Short vol48% DataJan 2020–Oct 2026 Filing10-K · Sep 28

Up next

Latest filing: 10-K
filed Sep 28, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-3.4%
Trailing year
Short interest
2.3%
Latest settlement · 1.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +8%
above
RSI (14) 56
neutral
MACD trend Positive
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +38%
trailing
6-month return +24%
trailing
YTD return +27%
this year
Relative strength +13%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.30% of float · ▼ -9.1% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Squeeze score 52
elevated · 0–100
Fundamentals
Fair
EPS growth +35%
Y/Y
Free cash flow $-7.8M
Quant / Vol
risk profile
Very High
Volatility 94%
annualized · 1-yr
Max drawdown −58%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+8% Bullish
RSI (14)
56 Neutral
MACD trend
Positive Bullish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +8 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.30% of float · ▼ -9.1% MoM · 1.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
48 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 50% Range high $2
vs 200-day avg +13% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NNVC
Nanoviricides, Inc.
this stock
$36.76M +27.4% — — 2.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.5% +46.2% 30.7 1.9%
MRNA
Moderna, Inc.
 $78.44B +566.3% +4.3% — 8.2%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.40B -3.9% +20.8% 18.4 2.5%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
48
% held
9.8%
Net QoQ
+559.5K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
587.6K
Days to cover
1.3d
Change
-58.5K sh
View
Short Volume
Short vol %
48%
As of
Oct 7, 2026
Short Total
View
Fails to Deliver
FTD shares
5.5K
Value
$6.1K
As of
Sep 8, 2026
View
Off-Exchange
Off-exchange %
54.7%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.2M
EPS diluted
$-0.41
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 29, 2026
This year
8
View
Exempt Offerings
Offering
$6.0M
Filed
Feb 25, 2026
View

Performance

5D 20D 120D MTD YTD
NNVC +10.8% +38.5% +24.1% +10.8% +27.4%
SPY +1.9% +1.9% +10.8% +1.9% +14.0%
vs SPY +8.9% +36.5% +13.4% +8.9% +13.5%
Key facts CIK 1379006 CUSIP 630087302 13F (30d) 1 filings 1 filers Visit website Investor relations